Lipid-lowering therapy and risk-based LDL-C goal attainment in Belgium: DA VINCI observational study.

Autor:	van de Borne P; Department of Cardiology, Erasme Hospital, University Libre of Brussels, Brussels, Belgium., Peeters A; Department of Neurology, Saint Luc University Clinic, Brussels, Belgium., Janssens L; Department of Cardiology, Imelda Hospital, Bonheiden, Belgium., Leone A; Department of Cardiology, Tivoli University Hospital Centre, La Louvière, Belgium., Lemmens R; Department of Neurology, University Hospitals Leuven and KU Leuven, Leuven, Belgium., Verhaegen A; Department of Endocrinology, Diabetes and Metabolism, Antwerp University Hospital, Edegem, Belgium., De Meulemeester M; GP, Private Practice, Gozée, Belgium., Balthazar Y; GP, Private Practice, Natoye, Belgium., Heijmans S; GP, Private Practice, Linkebeek, Belgium., Calozet Y; GP, Private Practice, Gribomont, Belgium., Paquot N; Department of Diabetology, Nutrition and Metabolic Diseases, Sart Tilman University Hospital Center, Liège, Belgium., Carlier S; Department of Cardiology, Ambroise Paré Hospital and University of Mons (UMONS), Mons, Belgium., Hemelsoet D; Department of Neurology, Ghent University Hospital, Ghent, Belgium., Bray S; Global Biostatistical Science, Amgen Ltd, Cambridge, UK., Ray KK; Imperial Centre for Cardiovascular Disease Prevention and Imperial Clinical Trials Unit, Imperial College London, London, UK.
Jazyk:	angličtina
Zdroj:	Acta cardiologica [Acta Cardiol] 2024 Feb; Vol. 79 (1), pp. 20-29. Date of Electronic Publication: 2022 Apr 20.
DOI:	10.1080/00015385.2022.2030568
Abstrakt:	Background: Cardiovascular disease (CVD) is one of the leading causes of death in Belgium. Current strategies for the prevention and management of CVD focus on reducing low-density lipoprotein cholesterol (LDL-C) levels. This analysis assessed whether LDL-C goals, recommended by the European Society of Cardiology (ESC)/European Atherosclerosis Society (EAS) guidelines, were being achieved in a Belgian study population. Methods: The cross-sectional, observational, DA VINCI study enrolled patients prescribed lipid-lowering therapy (LLT) between 21 June 2017 and 20 November 2018. Data for patients from Belgium were extracted for this country-specific analysis. Primary endpoint was the proportion of patients who achieved 2016 ESC/EAS risk-based LDL-C goals; attainment of 2019 risk-based LDL-C goals was evaluated post hoc . Results: Of 497 enrolled patients, 41% were female and mean age was 68 years. Among subjects with an LDL-C measurement on stabilised LLT, moderate-intensity statin monotherapy was the most prescribed LLT regimen (59%). Overall, 63% of patients achieved their risk-based LDL-C goals according to the 2016 ESC/EAS guidelines. Among patients with established ASCVD, risk-based LDL-C goal attainment was higher in patients with peripheral arterial disease (53%) than patients with coronary (37%) and cerebrovascular disease (42%). According to the updated 2019 ESC/EAS guidelines, less than half (41%) of patients achieved their risk-based LDL-C goal. The proportion of primary and secondary prevention patients who achieved 2019 risk-based LDL-C goals was 59% and 18%, respectively. Conclusion: These findings reveal a large gap between the LDL-C goals advocated by the ESC/EAS and the levels achieved in routine clinical practice in Belgium.
Databáze:	MEDLINE
Externí odkaz:	Zobrazit plný text záznamu